


Express Mail Label No.: EV074, 6669US
Date of Deposit: May 9, 2002

Attorney Docket No.: 22058-514 NATL

JC02 Rec'd PCT/PTO 09 MAY 2002



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Collins, *et al.*

SERIAL NUMBER : 09/868,123

FILING DATE : June 13, 2001

FOR : Cytokine Receptor Chains

EXAMINER : Not Yet Assigned

ART UNIT : Not Yet Assigned

RECEIVED

BOX IDS

Commissioner for Patents

Washington, D.C. 20231

AUG 01 2002



30623

PATENT TRADEMARK OFFICE

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (1 page), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate;
3. Copies of cited references A1-A3, B1-B2, and C1-C15; and
4. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 22058-514 NATL. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elmi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
Attorneys for Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: May 9, 2002



Express Mail Label No.: EV07 3669US
Date of Deposit: May 9, 2002

Attorney Docket No. 22058-514NATL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICANT(S): Collins, *et al.*
SERIAL NO.: 09/868,123
FILING DATE: June 13, 2001
FOR: Cytokine Receptor Chains

#6
RECEIVED

AUG 01 2002

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. A copy of each of the references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 22058-514 NATL.

Respectfully submitted,

Ivor R. Elrifi (Reg. No. 39,529)
David E. Johnson (Reg. No. 41,874)
Attorneys for Applicants
c/o MINTZ, LEVIN, COHN, FERRIS
GLOVSKY AND POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: May 9, 2002


Express Mail Label No.: EV074978669US

Date of Deposit: May 9, 2002

RECEIVED

AUG 01 2002

Page 1 of 2



Please type a plus sign (+) in this box



TECH CENTER 1600/2900

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/868,123
Filing Date of U.S. Natl Appl.	06/13/01
First Named Inventor	Collins
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	22058-514 NATL

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	5,696,234	12/09/97	Zurawski et al.			
	A2	5,599,905	02/04/97	Mosley et al.			
	A3	5,710,023	01/20/98	Collins et al.			

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 97/15663	Amrad Operations Pty. Ltd.	05/01/1997	
	B2	WO 94/04680	Schering Corporation	03/03/1194	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Obiri et al. (1995). "Receptor for Interleukin 13" <i>J. Biol. Chem.</i> 270(15): 8797-8804.
	C2	Vita et al. (1995). "Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types" <i>J. Biol. Chem.</i> 270(8): 3512-3517.
	C3	Zurawski et al. (1995). "The Primary Binding subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor" <i>J. Biol. Chem.</i> 270(23): 13869-13878.
	C4	International Search Report for PCT/US99/29493. Mailed on April 25, 2000.
	C5	Written Opinion for PCT/US99/29493. Mailed on January 26, 2001.
	C6	McKenzie et al. (1993). "Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function" <i>Proc. Natl. Acad. Sci. USA</i> 90: 3735-3739
	C7	Minty et al. (1993). "Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses" <i>Nature</i> 362: 248-250
	C8	Punnonen et al. (1994). "IL-13 Induces Proliferation, Ig Isotype Switching, and Ig Synthesis by Immature Human Fetal B Cells" <i>J. Immunol.</i> 152: 1094-1102
	C9	Punnonen et al. (1993). "Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells" <i>Proc. Natl. Acad. Sci. USA</i> 90: 3730-3734
	C10	Cocks et al. (1993). "IL-13 Induces Proliferation and Differentiation of Human B Cells Activated by the CD40 Ligand" <i>Int. Immunol.</i> 5(6): 657-663.
	C11	Zurawski et al. (1993). "Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction" <i>EMBO J.</i> 12: 2663-2670
	C12	Hilton et al. (1996). "Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor" <i>Proc. Natl. Acad. Sci. USA</i> 93: 497-501.
	C13	Shanafelt et al. (1998). "An immune cell-selective interleukin 4 agonist" <i>Proc. Natl. Acad. Sci. USA</i> 95: 9454-9458.

RECEIVED

AUG 01 2002

Page 2 of 2

TECH CENTER 1600/2900



Express Mail Label No.: EV074978669US

Date of Deposit: May 9, 2002

OTHER PRIOR ART -- NON-PATENT LITERATURE DOCUMENTS		
C14	Aversa et al. (1993). "An Interleukin 4 Mutant Protein Inhibits both IL-4 or IL-13 induced Human Immunoglobulin G4 and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors" <i>J. Exp. Med.</i> <u>178</u> : 2213-2218.	
C15	Grunewald et al. (1998). "An Antagonistic IL-4 Mutant Prevents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor system Completely Abrogates Humoral Immune Response to Allergen and Development of Allergic Symptoms In Vivo" <i>J. Immunol.</i> <u>160</u> : 4004-4009.	

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under *

35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.